## Sharanjot Saini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6755557/publications.pdf Version: 2024-02-01



SHADANIOT SAINI

#	Article	IF	CITATIONS
1	Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis. Clinical Cancer Research, 2011, 17, 5287-5298.	7.0	250
2	microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer. Cancer Research, 2018, 78, 1833-1844.	0.9	218
3	PSA and beyond: alternative prostate cancer biomarkers. Cellular Oncology (Dordrecht), 2016, 39, 97-106.	4.4	207
4	Curcumin Modulates MicroRNA-203–Mediated Regulation of the Src-Akt Axis in Bladder Cancer. Cancer Prevention Research, 2011, 4, 1698-1709.	1.5	181
5	MicroRNA-203 Inhibits Long Noncoding RNA HOTAIR and Regulates Tumorigenesis through Epithelial-to-mesenchymal Transition Pathway in Renal Cell Carcinoma. Molecular Cancer Therapeutics, 2018, 17, 1061-1069.	4.1	78
6	Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma. Molecular Cancer Research, 2017, 15, 884-895.	3.4	61
7	Role of Exosomes in Prostate Cancer Metastasis. International Journal of Molecular Sciences, 2021, 22, 3528.	4.1	56
8	MicroRNAs and epithelial-mesenchymal transition in prostate cancer. Oncotarget, 2016, 7, 67597-67611.	1.8	46
9	<i>BRN4</i> Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with <i>BRN2</i> . Clinical Cancer Research, 2019, 25, 6532-6545.	7.0	46
10	The complex roles of Wnt antagonists in RCC. Nature Reviews Urology, 2011, 8, 690-699.	3.8	33
11	Regulation of SRC Kinases by microRNA-3607 Located in a Frequently Deleted Locus in Prostate Cancer. Molecular Cancer Therapeutics, 2014, 13, 1952-1963.	4.1	31
12	MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer. Oncogene, 2020, 39, 7209-7223.	5.9	28
13	Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients. Scientific Reports, 2021, 11, 8279.	3.3	28
14	Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians. Oncotarget, 2017, 8, 8356-8368.	1.8	22
15	DNA mismatch repair gene MLH1 induces apoptosis in prostate cancer cells. Oncotarget, 2014, 5, 11297-11307.	1.8	17
16	Role of a novel race-related tumor suppressor microRNA located in frequently deleted chromosomal locus 8p21 in prostate cancer progression. Carcinogenesis, 2019, 40, 633-642.	2.8	15
17	Novel tumor suppressor microRNA at frequently deleted chromosomal region 8p21 regulates Epidermal Growth Factor Receptor in prostate cancer. Oncotarget, 2016, 7, 70388-70403.	1.8	15
18	miRNA Expression Analyses in Prostate Cancer Clinical Tissues. Journal of Visualized Experiments, 2015,	0.3	14

Sharanjot Saini

#	Article	IF	CITATIONS
19	Role of the PI3K/Akt pathway in cadmium induced malignant transformation of normal prostate epithelial cells. Toxicology and Applied Pharmacology, 2020, 409, 115308.	2.8	13
20	MicroRNAs as Regulators of Prostate Cancer Metastasis. Advances in Experimental Medicine and Biology, 2018, 1095, 83-100.	1.6	12
21	MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer. , 2020, 3, 804-818.		6
22	Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients. Journal of Visualized Experiments, 2019, , .	0.3	5
23	MicroRNA-4287 is a novel tumor suppressor microRNA controlling epithelial-to mesenchymal transition in prostate cancer. Oncotarget, 2020, 11, 4681-4692.	1.8	5
24	Coping with chemoresistance in prostate cancer—co-targeting of adipose stromal cells?. Translational Andrology and Urology, 2019, 8, S250-S253.	1.4	3
25	Role of MicroRNAs in Neuroendocrine Prostate Cancer. Non-coding RNA, 2022, 8, 25.	2.6	2